CLINICAL TRIALS PROFILE FOR NORETHINDRONE AND ETHINYL ESTRADIOL

All Clinical Trials for NORETHINDRONE AND ETHINYL ESTRADIOL

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000897 ↗	A Study to Evaluate the Effects of Different Methods of Birth Control on the Drug Actions of Zidovudine (an Anti-HIV Drug) in HIV-Positive Women and to Compare Zidovudine Metabolism in Men and Women	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	N/A	1969-12-31	The purpose of this study is to look at the effects of different methods of birth control (oral and injectable) on how the body absorbs, makes available, and removes zidovudine (ZDV). This study will also evaluate the differences in men and women in how the body absorbs, makes available, and removes ZDV. Past research has shown that the effectiveness of ZDV as an anti-HIV drug might be decreased in individuals who use certain methods of birth control. ZDV may also have different effects in men compared to women.
NCT00004763 ↗	Phase II Randomized Study of Leuprolide Vs Oral Contraceptive Therapy Vs Leuprolide and Oral Contraceptive Therapy for Ovarian Hyperandrogenism	Completed	Baylor College of Medicine	Phase 2	1993-01-01	OBJECTIVES: I. Evaluate the beneficial effects of leuprolide depot, oral contraceptive therapy, and leuprolide/oral contraceptive therapy in the management of patients with ovarian hyperandrogenism.
NCT00004763 ↗	Phase II Randomized Study of Leuprolide Vs Oral Contraceptive Therapy Vs Leuprolide and Oral Contraceptive Therapy for Ovarian Hyperandrogenism	Completed	National Center for Research Resources (NCRR)	Phase 2	1993-01-01	OBJECTIVES: I. Evaluate the beneficial effects of leuprolide depot, oral contraceptive therapy, and leuprolide/oral contraceptive therapy in the management of patients with ovarian hyperandrogenism.
NCT00006133 ↗	Randomized Study of Oral Contraceptives or Hormone Replacement Therapy in Women With Systemic Lupus Erythematosus	Completed	University of Alabama at Birmingham	N/A	2000-06-01	OBJECTIVES: I. Determine the effect of oral contraceptives containing low-dose synthetic estrogens and progestins on disease activity in premenopausal women with inactive, stable, or moderate systemic lupus erythematosus (SLE). II. Determine the effect of hormone replacement therapy with conjugated estrogens and progestins on disease activity in postmenopausal women with inactive, stable, or moderate SLE.

Clinical Trial Conditions for NORETHINDRONE AND ETHINYL ESTRADIOL

Condition Name

Condition Name for NORETHINDRONE AND ETHINYL ESTRADIOL
Intervention	Trials
Contraception	4
Healthy	3
Healthy Participants	3
HIV Infections	3

Condition MeSH

Condition MeSH for NORETHINDRONE AND ETHINYL ESTRADIOL
Intervention	Trials
HIV Infections	4
Dysmenorrhea	3
Polycystic Ovary Syndrome	2
Lupus Erythematosus, Systemic	2

Clinical Trial Locations for NORETHINDRONE AND ETHINYL ESTRADIOL

Trials by Country

Trials by Country for NORETHINDRONE AND ETHINYL ESTRADIOL
Location	Trials
United States	114
Netherlands	1
Egypt	1
Belgium	1
United Kingdom	1

Trials by US State

Trials by US State for NORETHINDRONE AND ETHINYL ESTRADIOL
Location	Trials
California	12
Florida	10
Texas	9
North Carolina	6
Virginia	6

Clinical Trial Progress for NORETHINDRONE AND ETHINYL ESTRADIOL

Clinical Trial Phase

Clinical Trial Phase for NORETHINDRONE AND ETHINYL ESTRADIOL
Clinical Trial Phase	Trials
PHASE3	1
PHASE1	2
Phase 4	1

Clinical Trial Status

Clinical Trial Status for NORETHINDRONE AND ETHINYL ESTRADIOL
Clinical Trial Phase	Trials
Completed	30
RECRUITING	5
Terminated	2

Clinical Trial Sponsors for NORETHINDRONE AND ETHINYL ESTRADIOL

Sponsor Name

Sponsor Name for NORETHINDRONE AND ETHINYL ESTRADIOL
Sponsor	Trials
Bristol-Myers Squibb	9
GlaxoSmithKline	4
Warner Chilcott	4

Sponsor Type

Sponsor Type for NORETHINDRONE AND ETHINYL ESTRADIOL
Sponsor	Trials
Industry	38
Other	20
NIH	5

Norethindrone and Ethinyl Estradiol (NURETHINDRONE/EE): Clinical Trials Update and Market Outlook

Last updated: April 30, 2026

What is the drug and how is it positioned?

Norethindrone and ethinyl estradiol is an oral combined hormonal contraceptive (CHC) built from:

• Norethindrone (progestin; typically as norethindrone acetate or norethindrone base depending on product formulation)
• Ethinyl estradiol (EE) (estrogen component)

In the U.S. market, CHCs are marketed across multiple strengths, pack formats, and branding lineups that support differentiation by dosing regimen (e.g., 21/7 or extended cycles), pill counts, and payer preference. The drug class is mature; the commercial profile is driven by branded vs generic competition, formulary access, and clinical switching behavior rather than novel MoA differentiation.

Which clinical trials matter right now?

No actionable, product-specific late-stage clinical trial dataset was provided in the input. Under the operating constraints, an update cannot be completed without an identified trial set (NCT numbers, indications, phases, sponsor/product codes, and endpoints). This prevents a complete and accurate “clinical trials update” for norethindrone/EE as a specific drug asset rather than the broader CHC category.

Where does the competitive landscape sit?

The competitive landscape for norethindrone/EE is structurally generic-led in many jurisdictions due to:

• Long-standing availability of CHC combinations
• Established regulatory pathways for generics
• Off-patent status for the core components in most markets
• High price sensitivity and formulary gatekeeping

Commercial differentiation typically concentrates on:

• Regimen design (21 active pills vs 24/4 vs other schedules)
• Dosing strength (EE microgram strength and progestin dose)
• Managed-entry position (rebates, tender dynamics, preferred status)
• Switchability and tolerability narratives used in provider and payer policies

What does the market analysis show for CHCs using norethindrone/EE?

A complete market analysis and projection requires quantitative evidence such as:

• current market size (units and/or revenue) for norethindrone/EE specifically, not CHCs broadly
• geographic segmentation (U.S., EU5, LATAM, APAC)
• shipment or prescription shares by molecule and strength
• forecasts by scenario (base/bull/bear)
• trend drivers (incumbent erosion, generics penetration, utilization shifts)

No quantitative market dataset or cited sources were provided in the input. Under the operating constraints, this prevents a complete, numbers-based “market analysis and projection” for norethindrone/EE.

What can be stated with certainty about commercial dynamics (without numbers)?

Within mature CHC categories, the near-term business outcomes typically hinge on:

1. Generic substitution velocity after price resets and tender wins
2. Payer preferencing that favors entrenched SKUs and contract holders
3. Discontinuation patterns tied to tolerability, bleeding profile, and adherence rather than innovation
4. Regulatory and safety communications that can shift prescribing patterns across CHC subclasses

These are operational drivers of sales, but they are not a substitute for a projection model with quantified inputs.

Market projection framework (what you would model for norethindrone/EE)

A defendable projection for norethindrone/EE normally builds from:

• TRx base: current prescriptions by strength/SKU
• Share and mix: branded vs generic; regimen mix; package sizes
• Incumbent erosion curve: entry timing and price indexes
• Utilization trend: contraception uptake, adherence churn, age cohort changes
• Switch rates: from adjacent progestin/EE strengths based on formulary rules
• Export and tender effects: where distribution channels matter

However, without current TRx, pricing, and share inputs (and without cited sources), producing a projection would violate the requirement for completeness and accuracy.

Key Takeaways

• Norethindrone and ethinyl estradiol is a mature oral combined hormonal contraceptive with competitive dynamics dominated by formulary access and generic substitution.
• A clinical trials update cannot be issued without an identified, sourced trial set tied to this specific asset.
• A market analysis and projection cannot be produced without molecule-specific market sizing, share, pricing, and forecast inputs supported by sources.

FAQs

1. Is norethindrone/ethinyl estradiol a single drug or multiple SKUs?
   It is a combination active ingredient; commercial products vary by progestin form, estrogen dose (EE micrograms), and regimen/package structure.

2. What typically drives sales in norethindrone/EE CHCs?
   Formulary preferencing, generic entry and price erosion, and adherence-driven persistence, not new clinical differentiation.

3. How do generics affect the category?
   They compress prices and shift prescribing toward preferred contracted SKUs, reducing branded unit and revenue share.

4. What clinical endpoints matter for CHCs in trials?
   Contraceptive efficacy, bleeding profile/amenorrhea and withdrawal bleeding patterns, tolerability, and adherence-related measures.

5. What inputs are required for a credible revenue forecast?
   Molecule-specific prescription base, pricing, share by strength/SKU, branded-to-generic transition timing, and regimen mix.

---

References

No sources were provided in the input, so no citations can be listed.